Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER):

Langue Français

Author :

Coudert, B ; Pierga, JY ; Mouret-Reynier, MA ; Kerrou, K ; Ferrero, JM ; Petit, T & al